Baminercept, an LTβR fusion protein that only blocks LTα1β2-LTβR interaction, was evaluated in two clinical trials and found not to be efficacious for the treatment of the signs and symptoms of RA. This evidence concerns the gene LTBR and rheumatoid arthritis.